Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Nurix Therapeutics, Inc. (NRIX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 47,040,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 15,218 35,430 43,924 56,372
Total Sell Value $172,193 $362,771 $427,193 $583,289
Total People Sold 3 3 3 4
Total Sell Transactions 5 10 16 32
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 173
  Page 3 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Wolff Stefani EVP and COO   •       –      –    2022-10-30 4 OE $0.00 $0 D/D 962 3,752     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2022-10-30 4 OE $0.00 $0 D/D 3,207 22,379     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2022-08-01 4 S $15.67 $18,585 D/D (1,186) 19,172     -
   Wolff Stefani EVP and COO   •       –      –    2022-08-01 4 S $15.67 $5,579 D/D (356) 1,238     -
   Van Houte Hans Chief Financial Officer   •       –      –    2022-08-01 4 S $15.67 $11,784 D/D (752) 72,656     -
   Ring Christine General Counsel   •       –      –    2022-08-01 4 S $15.67 $11,157 D/D (712) 4,615     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2022-07-30 4 OE $0.00 $0 D/D 3,207 20,358     -
   Wolff Stefani EVP and COO   •       –      –    2022-07-30 4 OE $0.00 $0 D/D 962 1,594     -
   Van Houte Hans Chief Financial Officer   •       –      –    2022-07-30 4 OE $0.00 $0 D/D 2,886 73,408     -
   Ring Christine General Counsel   •       –      –    2022-07-30 4 OE $0.00 $0 D/D 1,924 5,327     -
   Van Houte Hans Chief Financial Officer   •       –      –    2022-05-31 4 OE $0.84 $57,400 D/D 68,333 70,522     -
   Ring Christine General Counsel   •       –      –    2022-05-02 4 S $11.75 $7,755 D/D (660) 3,403     -
   Wolff Stefani EVP and COO   •       –      –    2022-05-02 4 S $11.75 $3,878 D/D (330) 632     -
   Van Houte Hans Chief Financial Officer   •       –      –    2022-05-02 4 S $11.75 $8,190 D/D (697) 2,189     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2022-05-02 4 S $11.75 $12,902 D/D (1,098) 17,151     -
   Ring Christine General Counsel   •       –      –    2022-04-30 4 OE $0.00 $0 D/D 1,924 4,063     -
   Wolff Stefani EVP and COO   •       –      –    2022-04-30 4 OE $0.00 $0 D/D 962 962     -
   Van Houte Hans Chief Financial Officer   •       –      –    2022-04-30 4 OE $0.00 $0 D/D 2,886 2,886     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2022-04-30 4 OE $0.00 $0 D/D 3,206 18,249     -
   Ring Christine General Counsel   •       –      –    2022-01-10 4 AS $27.14 $32,568 D/D (1,200) 1,286     -
   Ring Christine General Counsel   •       –      –    2022-01-10 4 OE $1.86 $2,232 D/D 1,200 2,486     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2022-01-03 4 AS $28.96 $52,939 D/D (1,828) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2022-01-03 4 OE $7.26 $16,570 D/D 1,828 16,025     -
   Ring Christine General Counsel   •       –      –    2021-12-10 4 AS $29.04 $34,848 D/D (1,200) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-12-10 4 OE $1.86 $2,232 D/D 1,200 2,486     -
  173 Records found
  1  2  3  4  5  6  7   
  Page 3 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us